Key statistics dashboard for Cellectar Biosciences, Inc. (CLRB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Stock Data
| Price | $2.35 |
| Market Cap | $19M |
| Enterprise Value | -$13.7M |
| Beta | 0.40 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.52 |
| Price / Book | 0.96 |
| P/S | 0.00 |
| EV/EBITDA | 0.61 |
| EV/Sales | 0.00 |
| EV/FCF | 0.70 |
| P/FCF | -0.96 |
| Earnings Yield | -77.66% |
| FCF Yield | -103.77% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -165.71% |
| Return on Assets | -60.93% |
| Return on Invested Capital | -74.93% |
| Return on Capital Employed | -74.94% |
Financial Health
| Current Ratio | 6.66 |
| Quick Ratio | 6.66 |
| Cash Ratio | 6.49 |
| Debt / Equity | 0.05 |
| Debt / Assets | 4.18% |
| Net Debt / EBITDA | 1.45 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -28.56 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.44 |
| Cash per share | 2.78 |
| FCF per share | -1.59 |
| Tangible Book Value per share | 2.44 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.88 |
Related companies: AEON · BOLT · CING · EVGN · IMNN · LYRA · MBIO
Explore sector: Healthcare · Biotechnology
More sections of CLRB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks